US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines

Hakariya, Hayase; Ozaki, Akihiko; Tanimoto, Tetsuya

dc.contributor.author	Hakariya, Hayase
dc.date.accessioned	2026-03-09T09:19:51Z
dc.date.available	2026-03-09T09:19:51Z
dc.date.issued	2025
dc.identifier.issn	0167-6997
dc.identifier.uri	http://hdl.handle.net/10900/176416
dc.language.iso	en	de_DE
dc.publisher	Dordrecht : Springer	de_DE
dc.relation.uri	http://dx.doi.org/10.1007/s10637-025-01524-9	de_DE
dc.subject.ddc	610	de_DE
dc.title	US FDA-accelerated approvals and subsequent withdrawals: influence on Japanese clinical oncology practice guidelines	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_01009
utue.publikation.seiten	311-317	de_DE
utue.personen.roh	Hakariya, Hayase
utue.personen.roh	Ozaki, Akihiko
utue.personen.roh	Tanimoto, Tetsuya
dcterms.isPartOf.ZSTitelID	Investigational New Drugs	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	43	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE
utue.fakultaet	07 Mathematisch-Naturwissenschaftliche Fakultät	de_DE